What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?

2020 ◽  
Vol 34 (5) ◽  
pp. 923-939
Author(s):  
Rory McCulloch ◽  
Toby A. Eyre ◽  
Simon Rule
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Mantle Cell Lymphoma ◽  
Kinase Inhibitor ◽  
Cell Lymphoma ◽  
Mantle Cell ◽  
Bruton Tyrosine Kinase ◽  
Inhibitor Resistance

scholarly journals Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Blood ◽  
2013 ◽  
Vol 122 (14) ◽  
pp. 2412-2424 ◽  
Author(s):  
Betty Y. Chang ◽  
Michelle Francesco ◽  
Martin F. M. De Rooij ◽  
Padmaja Magadala ◽  
Susanne M. Steggerda ◽  
...  
Keyword(s):  
Tyrosine Kinase Inhibitor ◽  
Mantle Cell Lymphoma ◽  
Peripheral Blood ◽  
Kinase Inhibitor ◽  
Cell Lymphoma ◽  
Key Points ◽  
Mantle Cell ◽  
Bruton Tyrosine Kinase ◽  
Btk Inhibitor ◽  
And Migration

Key Points MCL cells are mobilized into the peripheral blood of patients treated with the BTK inhibitor ibrutinib. Ibrutinib dose-dependently inhibits BCR- and chemokine-mediated adhesion and migration of MCL cells.

Sign in / Sign up

Export Citation Format

Share Document